Burzynski Research Institute, Inc. (the “Company”) was incorporated under the laws of the State of Delaware in 1984 in order to engage in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name “Antineoplastons.” The Company believes Antineoplastons are useful in the treatment of human cancer and is currently reviewing data of its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons have not been approved for sale or use by the Food and Drug Administration of the United States Department of Health and Human Services (“FDA”) or anywhere in the world. In the event Antineoplastons receive such approval and are registered in the United States, Canada, or Mexico, of which there can be no assurance, the Company will commence commercial operations, which shall include the production, marketing, promotion and sale of Antineoplastons in the United States, Canada, or Mexico. In 2004, the FDA approved the designation of Antineoplastons as an “orphan drug” under the Orphan Drug Act of 1983. See “Orphan Drug Designation” below for a detailed description of this designation and its meaning. The Company currently provides Antineoplastons solely for use by Stanislaw R. Burzynski, M.D., Ph.D. (“Dr. Burzynski”) in clinical research.
Company profile
Ticker
BZYR
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
IRS number
760136810
Calendar
14 Jul 22
9 Aug 22
28 Feb 23
Financial summary
Quarter (USD) | May 22 | Feb 22 | Nov 21 | Aug 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Feb 22 | Feb 21 | Feb 20 | Feb 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.77K | 4.77K | 4.77K | 4.77K | 4.77K | 4.77K |
Cash burn (monthly) | (no burn) | (no burn) | 77.25K | 74.34K | 13.04K | 23.32K |
Cash used (since last report) | n/a | n/a | 178.42K | 171.72K | 30.13K | 53.86K |
Cash remaining | n/a | n/a | -173.66K | -166.95K | -25.36K | -49.09K |
Runway (months of cash) | n/a | n/a | -2.2 | -2.2 | -1.9 | -2.1 |
Financial report summary
?Management Discussion
- Research and development costs were approximately $167,000 and $232,000 for the three months ended May 31, 2022 and 2021, respectively. The decrease of $65,000 or 28% was due to a decrease in personnel costs of $40,000, consulting and quality control costs of $4,000, facility and equipment costs of $20,000 and materials costs of $1,000, as a result of a reduction of requirements imposed by the Food and Drug Administration.
- General and administrative expenses were approximately $64,000 and $84,000 for the three months ended May 31, 2022 and 2021, respectively. The decrease of $20,000 or 24% was due to an decrease in legal and other professional costs of $21,000, offset by an increase in other costs of $1,000 as a result of a decrease in requests from regulatory agencies.
- The Company had net losses of approximately $232,000 and $316,000 for the three months ended May 31, 2022 and 2021, respectively. The decrease in the net loss from 2021 to 2022 is primarily due to an overall decrease in research and development costs and general and administrative expenses of the Company as described above.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
temporarily
Financial reports
Current reports
8-K
Departure of Directors or Certain Officers
6 Oct 21
8-K
Departure of Directors or Certain Officers
7 Jul 13
8-K
Entry into a Material Definitive Agreement
5 Jul 12
8-K
Departure of Directors or Certain Officers
29 Feb 12
8-K
Departure of Directors or Certain Officers
11 Sep 11
8-K
Changes in Registrant's Certifying Accountant
21 May 09
8-K
Departure of Directors or Principal Officers
23 Jan 06
8-K
Completion of Acquisition or Disposition of Assets
30 Nov 05
8-K
Burzynski Research Institute, Inc. and Millennium Energy Ventures.com, LLC Sign Agreement
9 Nov 04
8-K
Departure of Directors or Principal Officers
13 Oct 04
Registration and prospectus
No filings
Proxies
No filings
Patents
Utility
Methods for the treatment of leptomeningeal disease
31 May 22
Methods for the treatment of leptomeningeal disease in a pediatric patient.
Utility
Methods for the Treatment of Leptomeningeal Disease
20 May 21
Methods for the treatment of leptomeningeal disease in a pediatric patient.
Utility
Methods for the Treatment of Leptomeningeal Disease
11 Feb 21
Inventors: Stanislaw R. Burzynski